Study to Evaluate GLPG0634 in Subjects With Renal Impairment Compared to Healthy Subjects

Summary

This will be an open label study to assess the influence of renal impairment on the pharmacokinetics (PK) of GLPG0634 and its metabolite after once daily oral administrations of 100 mg GLPG0634 for 10 days in subjects with renal impairment and matched healthy controls. Also, safety and tolerability of once daily oral doses of GLPG0634 for 10 days in subjects with renal impairment and matched healthy controls will be evaluated.

Timeline

Start

2014-03

Primary completion

2014-07

Completion

2014-07

Drugs

Indications